Notice of Receipt of Grant
Filed with TSE · · 1 page · English
Summary by 6ix AI
Chordia Therapeutics Inc. announced the receipt of a grant for research and development related to cancer therapy. This funding will be recorded as non-operating income but will not impact the company's current fiscal year forecasts. The company specializes in oncology and is developing several clinical-stage assets.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Chordia Therapeutics Inc. on 6ix
Earlier from Chordia Therapeutics
- Non-consolidated Financial Results for the Nine Months Ended May 31 2026 [Japanese GAAP]
- TABLE-Chordia Therapeutics - 6-MTH parent results
- TABLE-Chordia Therapeutics - Q1 parent results
- TABLE-Chordia Therapeutics -2024/25 parent results
Later from Chordia Therapeutics
- Announcement Regarding the Review Status of Orphan Drug Designation for Rogocekib, a CLK Inhibitor
- Announcement of Orphan Drug Designation in Japan for rogocekib for Relapsed or Refractory AML
- Announcement Regarding Completion of Patient Enrollment in the Initial Expansion Cohort of rogocekib
- Announcement Regarding AMED Grant Award for rogocekib (CTX-712)
- Non-consolidated Financial Results for the Fiscal Year Ended August 31, 2026 [Japanese GAAP]
Follow Chordia Therapeutics into a list and get an email when it puts out news.
Follow Chordia Therapeutics